BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Prognosis
25 results:

  • 1. Papillary renal neoplasm with reverse polarity: a clinicopathologic study of 43 cases with a focus on the expression of kras signaling pathway downstream effectors.
    Kim B; Lee S; Moon KC
    Hum Pathol; 2023 Dec; 142():1-6. PubMed ID: 37797754
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Cyclin dependent kinase inhibitor 3 (CDKN3) upregulation is associated with unfavorable prognosis in clear cell renal cell carcinoma and shapes tumor immune microenvironment: A bioinformatics analysis.
    Al Sharie AH; Abu Zahra AM; El-Elimat T; Darweesh RF; Al-Khaldi AK; Abu Mousa BM; Amer MSB; Al Zu'bi YO; Al-Kammash K; Abu Lil A; Al Malkawi AA; Alazzeh Z; Alali FQ
    Medicine (Baltimore); 2023 Sep; 102(36):e35004. PubMed ID: 37682177
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
    Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
    Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
    Dong X; Liu T; Li Z; Zhai Y
    Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Comparative analyses of the prognosis, tumor immune microenvironment, and drug treatment response between left-sided and right-sided colon cancer by integrating scRNA-seq and bulk RNA-seq data.
    Cao L; Zhang S; Yao D; Ba Y; Weng Q; Yang J; Zhang H; Ren Y
    Aging (Albany NY); 2023 Jul; 15(14):7098-7123. PubMed ID: 37480572
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Primary retroperitoneal mucinous cystic neoplasm of borderline malignancy with
    Son SM; Woo CG; Yun SJ; Lee OJ
    J Int Med Res; 2023 May; 51(5):3000605231172469. PubMed ID: 37198972
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study.
    Myint KZY; Shimabuku M; Horio R; Kaneda M; Shimizu Y; Taguchi J
    Cancer Treat Res Commun; 2023; 35():100701. PubMed ID: 37094468
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective.
    Khan M; Ai M; Du K; Song J; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Zhang J; Tian Y; Yuan Y
    Front Immunol; 2022; 13():1062225. PubMed ID: 36605187
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Integrated Analysis of the Role of Enolase 2 in Clear Cell Renal Cell Carcinoma.
    Pan J; Jin Y; Xu X; Wei W; Pan H
    Dis Markers; 2022; 2022():6539203. PubMed ID: 36419844
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Papillary renal cell neoplasm with reverse polarity: A new subtype of renal tumour with favorable prognosis.
    Conde-Ferreirós M; Domínguez-de Dios J; Juaneda-Magdalena L; Bellas-Pereira A; San Miguel Fraile MP; Peteiro Cancelo MÁ; Gómez-de María C; Álvarez Sarria M; Betancor Santos MÁ; González-Carreró J; Ortiz-Rey JA
    Actas Urol Esp (Engl Ed); 2022 Dec; 46(10):600-605. PubMed ID: 36216763
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Clinicopathological features and diagnosis of pericytic tumors of the kidney].
    He YL; Zou YW; Hu YJ; Wu J; Zhang W; Yu WJ; Li YJ; Jiang YX
    Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):987-992. PubMed ID: 36207911
    [No Abstract]    [Full Text] [Related]  

  • 12. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
    Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
    Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Papillary renal neoplasm with reverse polarity with a favorable prognosis should be separated from papillary renal cell carcinoma.
    Liu Y; Zhang H; Li X; Wang S; Zhang Y; Zhang X; Xu T; Dong Y; Dong L; Zhou L; Yang X; Wang C
    Hum Pathol; 2022 Sep; 127():78-85. PubMed ID: 35724772
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Soluble PD-L1 as an early marker of progressive disease on nivolumab.
    Mahoney KM; Ross-Macdonald P; Yuan L; Song L; Veras E; Wind-Rotolo M; McDermott DF; Stephen Hodi F; Choueiri TK; Freeman GJ
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131863
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [Papillary renal neoplasm with reverse polarity: a clinicopathological analysis].
    Ji RH; Wang XT; Li R; Ye SB; Wang X; Ma HH; Lu ZF; Rao Q; Xia QY
    Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):23-27. PubMed ID: 34979749
    [No Abstract]    [Full Text] [Related]  

  • 16. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.
    Sun G; Chen J; Liang J; Yin X; Zhang M; Yao J; He N; Armstrong CM; Zheng L; Zhang X; Zhu S; Sun X; Yang X; Zhao W; Liao B; Pan X; Nie L; Yang L; Chen Y; Zhao J; Zhang H; Dai J; Shen Y; Liu J; Huang R; Liu J; Wang Z; Ni Y; Wei Q; Li X; Zhou Q; Huang H; Liu Z; Shen P; Chen N; Zeng H
    Nat Commun; 2021 Sep; 12(1):5262. PubMed ID: 34489456
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Morphological, immunohistochemical, and genomic analyses of papillary renal neoplasm with reverse polarity.
    Kiyozawa D; Kohashi K; Takamatsu D; Yamamoto T; Eto M; Iwasaki T; Motoshita J; Shimokama T; Kinjo M; Oshiro Y; Yonemasu H; Oda Y
    Hum Pathol; 2021 Jun; 112():48-58. PubMed ID: 33811832
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
    Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
    [No Abstract]    [Full Text] [Related]  

  • 19. Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma.
    Xiao W; Wang X; Wang T; Xing J
    Cancer Gene Ther; 2020 May; 27(5):330-340. PubMed ID: 31155610
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.
    Zhai W; Sun Y; Guo C; Hu G; Wang M; Zheng J; Lin W; Huang Q; Li G; Zheng J; Chang C
    Cell Death Differ; 2017 Sep; 24(9):1502-1517. PubMed ID: 28644440
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.